Approval · Notice of Compliance 11025 · 2010
FORTEO: Notice of Compliance 11025
Issued February 9, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11025
- Date
- February 9, 2010
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Extension of the maximum treatment period from 18 months to 24 months
- Therapeutic class
- Bone formation agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FORTEO | Not yet assigned | — |
Medicinal ingredients
- TERIPARATIDE 250 MCG per ML